Clinical Trial

YAG Laser Vitreolysis for Vitreous Floaters

Study acronym: YLV Protocol
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated February 27, 2026 (before its estimated May 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to measure how the quality of life, the structure of eye, and vision change after treatment for the opacities in the gel (vitreous) that fills the center of eye which cause vision disturbances commonly called "floaters". In this study the vitreous floaters are treated using a Neodymium-doped yttrium-aluminum-garnet (Nd:YAG) laser. The FDA has approved the use of this laser to treat membranes in the eye.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-03.
Trial Details
NCT Number NCT06915922
Lead Sponsor VMR Consulting, Inc.
Collaborators: The Retina Clinic - London Ophthalmic Institute
Conditions Posterior Vitreous Detachment, Myopic Vitreopathy, VISION DEGRADING MYODESOPSIA
Enrollment 50 participants
Start Date 2023-10-17
Primary Completion 2026-05 (estimated)
Study Completion 2026-05 (estimated)
Updated on ClinicalTrials.gov 2026-02-27